The global sterile injectables market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is expected to accelerate the growth of the market during the forecast period includes an increase in investment by manufacturers, to expand their business through new manufacturing facilities. For instance, in July 2019, Nexus Pharmaceuticals invested $250 million, for expanding its facility in Wisconsin, U.S. The new facility is expected to support the company in the production and supply of sterile injectable drugs to therapeutic areas, including anesthesia, oncology, cardiovascular, and neurology, among others. Moreover, in April 2019, Chr. Hansen Holding A/S, a global bioscience company, and Lonza AG, a pharma contract manufacturing company, received approvals from anti-trust regulators (it is a law in the U.S. to prevent large business corporations (trust)), to establish the 50/50 joint venture for live biotherapeutics products. Injectables are a compounded medication containing sterile drugs with therapeutic actions, which is administered in the body through the intravenous (IV) route of administration, with the help of needles and syringes. These sterile injectables are made up of small and large molecules (biologics).
To expand their sterile injectables product portfolio, manufacturers are developing sterile injectables, and are adopting strategies such as mergers and acquisitions and geographical expansion, which is another factor that is expected to boost the market growth during the forecast period. For instance, in June 2019, Lyophilization Services of New England (LSNE), a contract development and manufacturing organization (CDMO), acquired a sterile injectables manufacturing facility located in León, Spain. Through this acquisition, the site LSNE-León, will help LSNE to expand its existing manufacturing capabilities in Europe. The factor that is expected to restrain the global sterile injectables market growth includes product recall, due to sterility failure in injectables.
Market Coverage
Competitive Landscape: Baxter International Inc., Merck & Co., Inc., and Lonza Group Ltd., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Sterile Injectables Market Report by Segment
By Drug Type
• Monoclonal Antibodies
• Cytokines
• Insulin
• Peptide Hormones
• Blood Factors
• Immunoglobulins
• Others
By Therapeutic Application
• Cancer
• Diabetes
• Cardiovascular Diseases
• Autoimmune Diseases
• Infectious Diseases
• Pain
• Others
Global Sterile Injectables Market by Region
North America
Europe
Asia-Pacific
Rest of the World